Figure 4.Effect of Olaparib treatment on cell viability in MD2-overexpressing prostate cancer cellsBar graphs show the PARP-1 inhibitor Olaparib (10 μM, 48 h) on LNCaP control cells (PCMV vector) and MD2-overexpressing cells (MD2 vector). Data are presented as mean ± SEM; p < 0.01, Student’s t-test.
